Glaukos (FRA:6GJ) Long-Term Debt : €0.0 Mil (As of Dec. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Glaukos Long-Term Debt?

Glaukos's Long-Term Debt for the quarter that ended in Dec. 2024 was €0.0 Mil.

Glaukos's quarterly Long-Term Debt declined from Jun. 2024 (€52.7 Mil) to Sep. 2024 (€51.1 Mil) and declined from Sep. 2024 (€51.1 Mil) to Dec. 2024 (€0.0 Mil).

Glaukos's annual Long-Term Debt declined from Dec. 2022 (€265.6 Mil) to Dec. 2023 (€259.3 Mil) and declined from Dec. 2023 (€259.3 Mil) to Dec. 2024 (€0.0 Mil).

Glaukos Long-Term Debt Historical Data

The historical data trend for Glaukos's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Glaukos Long-Term Debt Chart

Glaukos Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Long-Term Debt

Get a 7-Day Free Trial

155.70

247.82

265.64

259.30

Glaukos Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Long-Term Debt	Get a 7-Day Free Trial															259.30	260.47	52.67	51.14	-

Glaukos (FRA:6GJ) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Glaukos Long-Term Debt Related Terms

Thank you for viewing the detailed overview of Glaukos's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Glaukos Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Glaukos Corp (FRA:6GJ) » Definitions » Long-Term Debt

Comparable Companies

Traded in Other Exchanges

GKOS:USA 6GJ:Germany

Address

One Glaukos Way, Aliso Viejo, CA, USA, 92656

Website

https://www.glaukos.com

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

Glaukos Headlines

No Headlines